Yukinori Kurokawa

Yukinori Kurokawa

Auto-generated profile, based on publicly available information

Yukinori Kurokawa

Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine , Osaka

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2018 in The Lancet Gastroenterology & Hepatology
Verified
Journal Article
Closed access
YKYukinori Kurokawa
Yukinori Kurokawa
YDYuichiro Doki
Yuichiro Doki
JMJunki Mizusawa
Junki Mizusawa
MTMasanori Terashima
Masanori Terashima
HKHitoshi Katai
Hitoshi Katai
MSMitsuru Sasako
Mitsuru Sasako

16 September 2014 in Gastric Cancer
Verified
Journal Article
Closed access
PDF file
YKYukinori Kurokawa
Yukinori Kurokawa
NMNariaki Matsuura
Nariaki Matsuura
YKYutaka Kimura
Yutaka Kimura
SAShinichi Adachi
Shinichi Adachi
JFJunya Fujita
Junya Fujita
YDYuichiro Doki
Yuichiro Doki

7 June 2022 in Annals of Oncology
Verified
Journal Article
Open access
YKY. Kurokawa
Y. Kurokawa
YHY. Honma
Y. Honma
ASA. Sawaki
A. Sawaki
YNY. Naito
Y. Naito
SIS. Iwagami
S. Iwagami
TDT. Doi
T. Doi
Prognosis of advanced gastrointestinal stromal tumors (GIST) refractory to tyrosine kinase inhibitors (TKIs) is poor. This randomized, placebo-controlled, phase III trial evaluated the efficacy and safety of pimitespib, a novel heat shock protein 90 inhibitor, in advanced GIST refractory to standard TKIs. Patients with histologically confirmed GIST refractory to imatinib, sunitinib, and regorafenib were randomized 2 : 1 to oral pimitespib 160 mg/day or placebo for 5 consecutive days per week in 21-day cycles. Following disease progression by blinded central radiological review (BCRR), cross-over to open-label pimitespib was permitted. The primary endpoint was progression-free survival (PFS) by BCRR in the full analysis set. Secondary endpoints included overall survival (OS) adjusted using the rank-preserving structural failure time (RPSFT) method to reduce the expected confounding impact of cross-over. From 31 October 2018 to 30 April 2020, 86 patients were randomized to pimitespib (n = 58) or placebo (n = 28). Median PFS was 2.8 months [95% confidence interval (CI) 1.6-2.9 months] with pimitespib versus 1.4 months (0.9-1.8 months) with placebo [hazard ratio (HR) 0.51 (95% CI 0.30-0.87); one-sided P = 0.006]. Pimitespib showed an improvement in cross-over-adjusted OS compared with placebo [HR 0.42 (0.21-0.85), one-sided P = 0.007]. Seventeen (60.7%) patients receiving placebo crossed-over to pimitespib; median PFS after cross-over was 2.7 months (95% CI 0.7-4.1 months). The most common (≥30%) treatment-related adverse events (AEs) with pimitespib were diarrhea (74.1%) and decreased appetite (31.0%); the most common (≥10%) grade ≥3 treatment-related AE was diarrhea (13.8%). Treatment-related AEs leading to pimitespib discontinuation occurred in three (5.2%) patients. Pimitespib significantly improved PFS and cross-over-adjusted OS compared with placebo and had an acceptable safety profile in patients with advanced GIST refractory to standard TKIs.

28 January 2014 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
YKY Kurokawa
Y Kurokawa
NSN Sugimoto
N Sugimoto
HMH Miwa
H Miwa
MTM Tsuda
M Tsuda
SNS Nishina
S Nishina
HFH Furukawa
H Furukawa
S-1, an oral fluoropyrimidine, plus cisplatin (SP) is a standard regimen for advanced gastric cancer (AGC) in East Asia. To date, no studies have evaluated the efficacy and safety of trastuzumab combined with SP in patients with human epidermal growth factor receptor type 2 (HER2)-positive AGC. Patients with HER2-positive AGC received S-1 (80–120 mg per day) orally on days 1–14, cisplatin (60 mg m−2) intravenously on day 1, and trastuzumab (course 1, 8 mg kg−1; course 2 onward, 6 mg kg−1) intravenously on day 1 of a 21-day cycle. The primary end point was response rate (RR); secondary end points included overall survival (OS), progression-free survival (PFS), time to treatment failure (TTF), and adverse events. A total of 56 patients were enrolled. In the full analysis set of 53 patients, the confirmed RR was 68% (95% confidence interval (CI)=54–80%), and the disease control rate was 94% (95% CI=84–99%). Median OS, PFS, and TTF were estimated as 16.0, 7.8, and 5.7 months, respectively. Major grade 3 or 4 adverse events included neutropaenia (36%), anorexia (23%), and anaemia (15%). Trastuzumab in combination with SP showed promising antitumour activity and manageable toxic effects in patients with HER2-positive AGC.

23 May 2017 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
YKYukinori Kurokawa
Yukinori Kurokawa
HYHan-Kwang Yang
Han-Kwang Yang
HCHaruhiko Cho
Haruhiko Cho
MRMin-Hee Ryu
Min-Hee Ryu
TMToru Masuzawa
Toru Masuzawa
YKYoon-Koo Kang
Yoon-Koo Kang
Background: Gastrointestinal stromal tumours (GISTs) with high-risk features have poor prognosis even if adjuvant treatment is given. Neoadjuvant imatinib may increase the cure rate by shrinking large GISTs and preserve organ function. Methods: We conducted an Asian multinational phase II study for patients with gastric GISTs ≥10 cm. Patients received neoadjuvant imatinib (400 mg/day) for 6–9 months. The primary end point was R0 resection rate. Results: A total of 56 patients were enroled in this study. In the full analysis set of 53 patients, neoadjuvant imatinib for ≥6 months was completed in 46 patients. Grade 3–4 neutropenia and rash occurred in 8% and 9%, respectively, but there were no treatment-related deaths. The response rate by RECIST was 62% (95% CI, 48–75%). The R0 resection rate was 91% (48/53) (95% CI, 79–97%). Preservation of at least half of the stomach was achieved in 42 of 48 patients with R0 resection. At the median follow-up time of 32 months, 2-year overall and progression-free survival rates were 98% and 89%, respectively. Conclusions: Neoadjuvant imatinib treatment for 6–9 months is a promising treatment for large gastric GISTs, allowing a high R0 resection rate with acceptable toxicity.

1 March 2015 in Surgery
Verified
Journal Article
Closed access
YKYukinori Kurokawa
Yukinori Kurokawa
NHNaoki Hiki
Naoki Hiki
TYTakaki Yoshikawa
Takaki Yoshikawa
KKKentaro Kishi
Kentaro Kishi
YIYuichi Ito
Yuichi Ito
HTHiroya Takeuchi
Hiroya Takeuchi